According to the Kaplan–Meier analysis results (Figure 7), higher levels of RBM8A mRNA indicated worse overall survival in esophageal adenocarcinoma (P = 0.029), kidney renal papillary cell carcinoma (P = 0.044), liver hepatocellular carcinoma (P = 0.0085), pancreatic ductal adenocarcinoma (P = 0.013), pheochromocytoma and paraganglioma (P = 0.042), and sarcoma (P = 0.0076). Here, RBM8A is linked to paraganglioma.